Table 1.

General characteristics of the study population, according to PE protocol.

	General Population	AET	RET	p-Value
	(n = 57)	(n = 31)	(n = 26)
Age, years	53.1 ± 6.8
TA, %	72.14 ± 24.5	66.0 ± 29.9	79.3 ± 13.8	0.042
PE protocol, n (%)				0.001
AET	31 (54.4%)	14 (45.2%)	0 (0%)
W	17 (29.8%)	0 (0%)	26 (100%)
NW	14 (24.6%)	17 (54.8%)	0 (0%)
RET	26 (45.6%)
BC recurrence, n (%)	2 (3.6%)	2 (6.5%)	0 (0%)	0.19
RT, n (%)	19 (33.3%)	7 (22.6%)	12 (46.2%)	0.06
HT, n (%)	39 (68.4%)	17 (54.8%)	21 (80.8%)	0.039
AIs, n (%)	24 (42.2%)	8 (25.8%)	16 (61.5%)	0.039
Tamoxifen, n (%)	15 (27.3%)	10 (32%)	5 (19.2%)	0.27
CV therapy, n (%)
Statins, n (%)	1 (1.7%)	1 (3.2%)	0 (0%)	0.36
BB, n (%)	6 (10.5%)	1 (3.2%)	5 (19.2%)	0.05
ACE-I, n (%)	11 (19.3%)	4 (12.9%)	7 (26.9%)	0.18
APT, n (%)	4 (1.7%)	3 (9.7%)	1 (3.9%)	0.39
CCB, n (%)	1 (1.7%)	1 (3.2%)	0 (0%)	0.36
Diuretics, n (%)	6 (10.5%)	2 (6.5%)	4 (15.4%)	0.27
SF-36
PF	80 [65, 85]	80 [60, 85]	80 [70, 90]	0.22
SC	75 [62, 87]	75 [50, 100]	75 [62, 87]	0.25
MH	64 [52, 76]	64 [48, 76]	64 [52, 80]	0.45
P	52 [41, 74]	52 [41, 74]	52 [41, 84]	0.59
RLP	75 [25, 100]	50 [25, 100]	75 [10, 100]	0.95
RLM	66 [33, 100]	66 [0, 100]	66 [33, 100]	0.67
EV	55 [45, 65]	55 [40, 65]	55 [45, 65]	0.44
HP	56 [42, 72]	55 [42, 82]	56 [40, 72]	0.72

List of the abbreviations: AET, aerobic exercise training; RET, resistance exercise training; W, walking; NW, Nordic walking; TA, total adherence to PE program; RT, radiotherapy; HT, hormone therapy; AIs, aromatase inhibitors; CV, cardiovascular; BB, beta-blockers; ACE-I, ACE-inhibitors; APT, antiplatelet therapy; CCB, calcium channel blockers; SF-36, Short Form Health Survey-36; PF, physical function; SC, social function; MH, mental health; P, pain; RLP, role limitation physical; RLM, role limitation mental; EV, vital energy; HP, health perception. Bold values denote statistical significance at the p < 0.05 level.